No time to wait: Evolving testing & treatment landscape in early stage lung cancer
Lung cancer has seen tremendous advancements over the past decade with the emergence of targeted therapies directed against mutant onco-proteins and immune checkpoint inhibitors. Until recently, these advances were predominantly in the advanced metastatic setting. The approvals of osimertinib, the first targeted therapy directed against EGFR for adjuvant use and atezolizumab , the first immune-checkpoint inhibitor to be FDA-approved for adjuvant use have brought much needed advancement in the post-operative setting. Please join our live webinar on 10th August to hear thoracic multidisciplinary teams of pathologists, surgeons and oncologists from Korea and Thailand share updates in the testing and treatment setting for early stage non-small cell lung cancer.